Yosemite Advances Cancer Drug Pipeline Amid Patent Cliff Challenges

Yosemite, an oncology-focused venture firm, is attempting to de-risk early-stage academic research by combining philanthropic grants with venture capital to build biotech companies from the ground up.

Startups, Policy & World Desk
Updated Nov 9, 2026 2 min read
Yosemite Advances Cancer Drug Pipeline Amid Patent Cliff Challenges

Since its 2023 launch, Yosemite has focused on a specific model: building oncology companies from scratch rather than merely investing in existing ones. According to TechCrunch, the firm operates with the belief that the next generation of cancer cures will not be found within existing pharmaceutical pipelines, but must be created through new research. By utilizing a mix of philanthropic funding and outside investment capital, Yosemite aims to de-risk early academic ideas before they mature into full-scale clinical ventures. The firm, which has 20 companies in its first fund, targets a specific niche that founder Reed Jobs notes comprises 40% of the biotech industry.

The firm’s technical strategy centers on areas where traditional drug discovery has historically struggled. According to TechCrunch, Yosemite is prioritizing "induced proximity"—a method where a drug physically drags a disease-causing protein toward a cell’s breakdown system rather than attempting to block it directly. Other focus areas include epigenetic gene editing, which modifies how a gene is expressed without altering the underlying DNA sequence, and improving the delivery of gene editing tools to specific cells. These approaches are designed to address biological targets that were previously considered unreachable or "undruggable" by conventional chemical methods.

Yosemite’s portfolio includes companies like Azalea, which originated from a grant to Jennifer Doudna’s lab and is currently in clinical trials, and Quarry, a company built in collaboration with serial founder Craig Crews. The firm’s operational model allocates about one-third of its capital to companies it builds internally, often in partnership with institutions such as Yale, Stanford, and Berkeley. The remaining capital is deployed into external companies that align with the firm’s oncology-specific focus. This hybrid approach is intended to allow Yosemite to create new areas of medicine before they become widely recognized by the broader venture capital community.

Beyond therapeutic development, Yosemite is betting on artificial intelligence to solve the inefficiencies inherent in clinical trials. According to TechCrunch, the firm is exploring the use of synthetic control arms—computer-generated stand-ins for untreated patient groups—to reduce the number of patients required for trials, thereby increasing speed and lowering costs. Jobs argues that AI is also democratizing science by accelerating the "grunt work" of drug discovery, allowing researchers to identify and interact with protein pockets that were historically impossible to target, such as the KRAS gene, which has long been a challenge in pancreatic cancer treatment.

The firm’s activities occur against a backdrop of significant shifts in the pharmaceutical sector. According to TechCrunch, the industry is currently navigating its largest patent cliff in history, a situation exacerbated by record cash reserves accumulated during the pandemic. This environment has driven a recent spree of acquisitions, with major players seeking to replenish their pipelines. Yosemite’s strategy of building companies from early academic research is positioned to capitalize on this demand, as the firm attempts to navigate the intersection of high-risk scientific innovation and the urgent need for new oncology therapies.

Sources

  1. 01 Reed Jobs would rather talk about curing cancer than his last name — TechCrunch
#biotech #oncology #drug-development #venture-capital